Emerging Biotech's Breakthrough in Pancreatic Cancer Trial Targets $1 Billion Market…(29)(33)
See why now may be the best time to start your research on RenovoRx Inc. (Nasdaq: RNXT).
Pioneering Change in Pancreatic Cancer Care (34)
Image Source (35)
Pancreatic cancer, often detected at an advanced stage, poses a formidable challenge for patients and doctors alike. Among these stages, stage 4, or metastatic pancreatic cancer, is particularly grim as it signifies the cancer’s spread to distant parts of the body, making it difficult to treat effectively.
Stage 4 pancreatic cancer, also known as metastatic pancreatic cancer, is marked by cancer cells spreading to vital organs. Survival rates at this stage are disheartening, ranging from 2% to 12%, with factors like age influencing outcomes.
Given the limited chances of a cure, the focus shifts to palliative care, aiming to alleviate pain, improve comfort, and address emotional needs, ultimately enhancing patients’ quality of life.
Despite the challenges, medical research strives to offer hope.
RenovoRx, Inc. (Nasdaq: RNXT) stands at the forefront, pioneering treatments like the Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. Though currently focused on locally advanced pancreatic cancer, RenovoRx’s dedication may herald hope for stage 4 patients in the future.
Image Source (33)
Keep reading to see why RenovoRx, Inc. (Nasdaq: RNXT) needs to be at the top of your daily watch-list.
7 Reasons Why RenovoRx, Inc. (Nasdaq: RNXT) Could Be Poised For Significant Upside Potential Ahead of 2024.
1. Analyst Coverage:
Generally speaking, when it comes to Wall Street, a target is a range at which an analyst believes a stock to be fairly valued relative to its projected and historical earnings. When an analyst assigns a target for a stock, they generally expect the stock price to rise or fall accordingly.(12) According to financial news portal TipRanks, RenovoRx, Inc. (Nasdaq: RNXT) received a $14 target from Scott Henry of I-Banking Firm, Roth MKM. (31) This would indicate an upside potential of over 1,438% from the company's 52-week low of $.91 set on 10/2/2023.(2)
2. Extremely Low-Float:
Market participants typically consider a float of 10-to-20 million shares as a low float. Some larger corporations have very high floats in the billions.(3) According to FinViz.com RenovoRx, Inc. (Nasdaq: RNXT) has less than 8.9M shares available in float as of 11/14/2023.(4) A low-float stock can make significant moves due to volatility from so few shares being available (3), so this could be an interesting situation to watch closely.
3. Groundbreaking TAMP™ Therapy Platform:
The Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, currently in a Phase III clinical trial for pancreatic cancer, represents a potential game-changer in cancer treatment. The platform's precision in delivering targeted therapy, as demonstrated by positive interim analysis results, indicates its potential to enhance treatment outcomes and reduce adverse events. RenovoRx, Inc. (Nasdaq: RNXT) is at the forefront of this innovative approach. (29)
4. Strategic Collaboration with Imugene: RenovoRx, Inc. (Nasdaq:
RNXT)’s collaboration with Imugene Ltd to explore oncolytic virus therapy using the TAMP™ platform not only validates its technology but also expands its application from chemotherapy to immunotherapy. This strategic partnership opens doors to innovative treatment approaches and positions RenovoRx, Inc. (Nasdaq: RNXT) as a player in the evolving field of cancer immunotherapy. (29)
5. Financial Stability and Responsibility:
In terms of financial performance, the company's commitment to advancing cancer research while maintaining fiscal responsibility is evident. With a cash position of $3.2 million as of September 30, 2023, and improved net loss figures, RenovoRx, Inc. (Nasdaq: RNXT) has demonstrated its ability to manage expenses efficiently, instilling confidence in its long-term prospects.(29)
6. Promising Clinical Trial Progress:
The successful interim analysis of the Phase III TIGeR-PaC clinical trial, which aims for a 6-month Overall Survival (OS) benefit, is a significant milestone. The Data Monitoring Committee's recommendation to continue the trial indicates the potential effectiveness of RenovoRx, Inc. (Nasdaq: RNXT)’s TAMP™ platform in treating pancreatic cancer. Industry stakeholders may see value in the company's progress toward meeting primary and secondary endpoints.(29)
7. Visionary Leadership:
CEO Shaun Bagai's commitment to improving cancer care and delivering novel targeted combination therapies is evident in RenovoRx, Inc. (Nasdaq: RNXT)’s mission. His leadership and the company's focus on transformative solutions position RenovoRx as a player with a vision to alter the current paradigm of oncology care.(29)
RenovoRx, Inc. (Nasdaq: RNXT) Receives $14.00 Target, Which Could Indicate an Upside Potential of Over 1,438% From its 52-Week Low… (31)(2)
Chart Source (11)
Generally speaking, when it comes to Wall Street, a target is a range at which an analyst believes a stock to be fairly valued relative to its projected and historical earnings. When an analyst raises their target for a stock, they generally expect the stock price to rise.(12)
A target is an analyst’s projection of a security’s future range. Targets can pertain to all types of securities, from complex financial products to stocks and bonds. When setting a stock’s target, an analyst is trying to determine what the stock is worth and what the range could be in 12 or 18 months. Ultimately, targets depend on the valuation of the company that’s issuing the stock.(12)
Analysts generally publish their targets in research reports on specific companies, along with their buy, sell, and hold recommendations for the company’s stock. Stock targets are often quoted in the financial news media.(12)
And this time, Benzinga.com(30) and TipRanks(31) are both indicating that RenovoRx, Inc. (Nasdaq: RNXT) has received analyst coverage from I-Banking Firm, Roth MKM. TipRanks is reporting that RenovoRx, Inc. (Nasdaq: RNXT) has been assigned a $14.00 target by analyst Scott Henry of Roth MKM. This would indicate an upside potential of over 1,438% from RenovoRx, Inc. (Nasdaq: RNXT)’s 52-week low of $.91 set on 10/2/2023, according to Barchart.com’s pricing history.(2)
Looking at RenovoRx, Inc.’s (Nasdaq: RNXT)’s chart above you can see what a 1,438% move would look like…
That isn’t to say a move like that is certain, but an analyst’s target is something important to take into account.
Then taking a deeper dive into StockCharts.com (below), you’ll see the following moving averages:
- Daily Average Price: $1.10 as of 11/14/2023
- 50 Day Moving Average $1.23
- 100 Day Moving Average $1.60
- 200 Day Moving Average $2.30
- 52-Week Low: $.91 according to Barchart.com. (2)
- 52-Week High $5.74 according to Barchart.com. (2)
- Roth MKM Target: $14.00 (31)
Keep reading to see why RenovoRx, Inc.’s (Nasdaq: RNXT) deserves a top spot on your daily watch list.
RenovoRx, Inc. (Nasdaq: RNXT) Has an Extreme Low-Float.(3)(4)
Low float stocks refer to the securities that remain after a company’s stock has been issued to its controlling investors — meaning there are relatively few shares for the public to buy.(3)
Market participants typically consider a float of 10-to-20 million shares as a low float. Some larger corporations have very high floats in the billions.(3)
Companies with a low float frequently have a large portion of their equity held by controlling investors such as directors and employees, which leaves only a tiny percentage of the stock available for public trading. (3)
That limited supply can cause dramatic price swings if demand changes quickly.(3)
Because low-float stocks have fewer shares available, market participants may have difficulty finding shares available.(3)
Low float stocks have the potential to present significant swings as active market participants take notice.(3)
RenovoRx, Inc. (Nasdaq: RNXT) has less than 8.9M shares available in its float (as of 11/14/2023) according to FinViz.com.(4) A low-float stock can make significant moves due to volatility from so few shares being available(3), so this could be one interesting situation to watch closely.
RenovoRx, Inc. (Nasdaq: RNXT) is also considered a nano-cap. In general, nano-cap companies have market capitalizations of less than $50 million.(5) Because nano-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly.(6)
As of 11/14/2023, RenovoRx, Inc. (Nasdaq: RNXT) has a market cap of approximately $11.23M according to MarketWatch.com.(22)
Which is why things could get very interesting and also why you need to start your research on RenovoRx, Inc. (Nasdaq: RNXT).
RenovoRx, Inc. (Nasdaq: RNXT) Strengthens Its Intellectual Property (IP) Portfolio with Their 8th US Patent. (7)
RenovoRx, Inc. (Nasdaq: RNXT) Strengthens Its Intellectual Property (IP) Portfolio with Their 8th US Patent. bolstering the 7 years of Post-Approval Market Exclusivity That they Currently have with their Lead Oncology Product Candidate, RenovoGem™, Through the Orphan Drug Designation granted by the FDA for their first two indications…(7)
RenovoRx, Inc. (Nasdaq: RNXT) has strengthened its Intellectual Property (IP) portfolio with the issuance of its eighth US patent. This patent, numbered 11,541,211, encompasses methods for treating cholangiocarcinoma (bile duct cancer) by selectively delivering therapeutic agents into targeted areas of the bile duct. RenovoRx’s CEO, Shaun Bagai, emphasized the significance of this new addition to their IP portfolio, which now comprises eight US method and device patents, one EU delivery system patent, and eight pending patents across the US, EU, and Asia.(7)
This latest patent also reinforces the company’s seven years of post-approval market exclusivity for their lead oncology product candidate, RenovoGem™, through FDA-granted Orphan Drug designation for their first two indications: Locally Advanced Pancreatic Cancer (LAPC) and Extrahepatic Cholangiocarcinoma (eCCA) or Bile Duct Cancer.
Image Source (33)
SUBSCRIBE TO OUR NEWSLETTER FOR MUST READ REPORTS & NEWS.
Getting the Right News Before Everyone Else Does, is FREE…
Terms | Privacy Policy Message and data rates may apply. Reply STOP keyword to be opted out of the program. Reply Help for Help. We will never sell or share to third parties. For informational purposes only.
How Patients and Physicians Experience RenovoTAMPTherapy(9)
- Interventional Radiology Lab-based procedure.
- Patient under local anesthetic/conscious sedation.
- RenovoCathinserted through femoral artery.
- Using a contrast agent under x-ray fluoroscopy, blood vessel segment adjacent to the tumor is isolated by adjusting balloon placement.
- 120mL of gemcitabine/saline delivered over 20 minutes.
- RenovoTAMP Procedure takes approximately 90 minutes.
- Catheter placement.
- Drug infusion.
- Catheter removal and access site hemostasis.
- Patient moved to the recovery room and was discharged the same day.
- RenovoTAMP Procedure repeated every 2 weeks over 4 months (8 treatments).
- Procedure easy to learn:physicians are proctored for the first 2-3 procedures.
RenovoRx, Inc. (Nasdaq: RNXT) Employs De-risked Small Molecule Chemotherapy Drugs First Drug Candidate: Intra-Arterial Gemcitabine (9)
- IV (systemic) gemcitabine has been marketed in the US since 1996.
- Established as part of the current standard of care for pancreatic cancer and other solid tumors.
- Potent anti-tumor agent: cell phase specificity primarily killing cells undergoing DNA synthesis (S-phase).
- Preclinical studies: inhibits 80-100% of tumor growth with subsequent increases in lifespan.
- Limitations of IV/systemic delivery of gemcitabine include poor tumor tissue penetration and high systemic toxicity.
- Intra-arterial gemcitabine for treatment of solid tumors.
- FDA Orphan Drug Designation (7 years marketing exclusivity post-approval) for pancreatic cancer and CCA.
- Phase 1/2 and observational registry trial data demonstrated an increase in overall survival time in patients with LAPC.
- Median survival of 27.9 months (including radiation pre-treatment) vs. 12-15 months historical control.
The proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform aims to avoid the harsh side effects typical of the current standard of care, thus improving patient well-being and extension of life so more time may be enjoyed with loved ones.
RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and its patented delivery system, RenovoCath®, and is regulated by the FDA.(7)
Image Source (9)
Image Source (9)
RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer (cholangiocarcinoma).(7)
Meet the Management Team Leading RenovoRx, Inc. (Nasdaq: RNXT) Into 2023
RenovoRx, Inc. (Nasdaq: RNXT) Highlights (33)
- De-risked drug development and validated TAMP platform
- Large first indication market ($1B) and platform broadly applicable to growing market segment
- Experienced clinical and commercial Leadership Team and Board
- First RenovoGem Phase III interim analysis completed 1H ’23 – presented positive results at AACR 2023 and ESMO GI 2023:
- 6-month Overall Survival benefit
- 8-month progression-free survival benefit
- >65% reduction in side effects
Potential Upcoming Milestones (33)
Image Source (33)
Phase III Trial News: RenovoRx, Inc. (Nasdaq: RNXT)’s Innovative Therapy Platform Shows Promise in Pancreatic Cancer Treatment Study.(25)
Promising interim data analysis has shown a 60% improvement in median overall survival and a significant 65% reduction in side effects compared to standard treatment. Dr. Salwan Al Mutar, Principal Investigator, highlighted the significance of targeted, intra-arterial chemotherapy for pancreatic cancer patients. Dr. Ramtin Agah, RenovoRx’s CMO, praised UT Southwestern’s involvement, emphasizing the shared vision of enhancing cancer patient outcomes. UT Southwestern Medical Center joins other clinical trial sites across the U.S. in enrolling patients for this groundbreaking study, offering hope for improved pancreatic cancer treatment options.(25)
RenovoRx, Inc. (Nasdaq: RNXT) Reports Q3 2023 Financial Results and Advances in Cancer Care… (29)
The company continues to make significant strides in its mission to revolutionize cancer treatment, notably through its pioneering Trans-Arterial Micro-Perfusion (TAMP™) platform and strategic collaborations.
TAMP™ Therapy Platform: A Potential Game-Changer (29)
At the heart of RenovoRx’s recent successes lies its proprietary TAMP™ therapy platform. The TAMP™ platform, currently undergoing a Phase III clinical trial for the treatment of Pancreatic Cancer, has generated excitement within the medical community. Notably, an interim analysis conducted in March 2023 received a favorable recommendation from the Data Monitoring Committee, paving the way for the trial’s continuation.
The Phase III TIGeR-PaC clinical trial prespecifies a primary endpoint of a 6-month Overall Survival (OS) benefit, accompanied by secondary endpoints focused on reducing adverse events compared to standard care. Dr. Michael J. Pishvaian, Principal Investigator of TIGeR-PaC, showcased the potential of the TAMP™ therapy platform at the Global Summit on Gastrointestinal Malignancies. His presentation highlighted the platform’s precision in delivering targeted cancer treatment, promising increased safety, tolerance, and efficacy.
Image Source (33)
RenovoRx’s strategic collaboration with Imugene Ltd (ASX: IMU) underscores its commitment to broadening the scope of cancer care. This partnership not only validates the TAMP™ platform but also extends its use from chemotherapy to immunotherapy. By exploring the delivery of oncolytic virus therapy using TAMP™, RenovoRx aims to enhance treatment options and redefine cancer care paradigms.
RenovoRx’s financial results for the third quarter ended September 30, 2023, highlight its dedication to advancing cancer research and development while maintaining fiscal responsibility:
Cash Position: As of September 30, 2023, RenovoRx held $3.2 million in cash and cash equivalents, ensuring the company’s ability to continue its vital work.
R&D Expenses: Research and development expenses totaled $1.6 million for the quarter, reflecting ongoing Phase III clinical trial costs and increased employee-related benefits expenses. This investment in research underscores RenovoRx’s commitment to pushing the boundaries of cancer treatment.
G&A Expenses: General and administrative expenses remained stable at $1.3 million for the third quarter of 2023 compared to the same period last year. While employee and related benefits costs increased, this was offset by decreased insurance expenses and a reallocation of administrative expenses to research and development.
Shares Outstanding: As of September 30, 2023, RenovoRx had 10,693,080 shares of common stock outstanding.
RenovoRx’s progress in its pivotal Phase III TIGeR-PaC study, its partnership with Imugene, and its financial stability are all indicative of a company poised to make a lasting impact in the field of oncology. As it continues to push the boundaries of cancer treatment, RenovoRx holds great promise for patients, offering new hope for those facing challenging diagnosis.(29)
Emerging Biotech's Breakthrough in Pancreatic Cancer Trial Targets $1 Billion Market…(29)(33)
See why now may be the best time to start your research on RenovoRx Inc. (Nasdaq: RNXT).
7 Reasons Why RenovoRx, Inc. (Nasdaq: RNXT) Could Be Poised For Significant Upside Potential ahead of 2024.
1. Analyst Coverage:
Generally speaking, when it comes to Wall Street, a target is a range at which an analyst believes a stock to be fairly valued relative to its projected and historical earnings. When an analyst assigns a target for a stock, they generally expect the stock price to rise or fall accordingly.(12) According to financial news portal TipRanks, RenovoRx, Inc. (Nasdaq: RNXT) received a $14 target from Scott Henry of I-Banking Firm, Roth MKM. (31) This would indicate an upside potential of over 1,438% from the company's 52-week low of $.91 set on 10/2/2023. (2)
2. Extremely Low-Float:
Market participants typically consider a float of 10-to-20 million shares as a low float. Some larger corporations have very high floats in the billions.(3) According to FinViz.com RenovoRx, Inc. (Nasdaq: RNXT) has less than 8.9M shares available in float as of 11/14/2023.(4) A low-float stock can make significant moves due to volatility from so few shares being available(3), so this could be an interesting situation to watch closely.
3. Groundbreaking TAMP™ Therapy Platform:
The Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, currently in a Phase III clinical trial for pancreatic cancer, represents a potential game-changer in cancer treatment. The platform's precision in delivering targeted therapy, as demonstrated by positive interim analysis results, indicates its potential to enhance treatment outcomes and reduce adverse events. RenovoRx, Inc. (Nasdaq: RNXT) is at the forefront of this innovative approach. (29)
4. Strategic Collaboration with Imugene: RenovoRx, Inc. (Nasdaq:
RNXT)’s collaboration with Imugene Ltd to explore oncolytic virus therapy using the TAMP™ platform not only validates its technology but also expands its application from chemotherapy to immunotherapy. This strategic partnership opens doors to innovative treatment approaches and positions RenovoRx, Inc. (Nasdaq: RNXT) as a player in the evolving field of cancer immunotherapy. (29)
5. Financial Stability and Responsibility:
In terms of financial performance, the company's commitment to advancing cancer research while maintaining fiscal responsibility is evident. With a cash position of $3.2 million as of September 30, 2023, and improved net loss figures, RenovoRx, Inc. (Nasdaq: RNXT) has demonstrated its ability to manage expenses efficiently, instilling confidence in its long-term prospects. (29)
6. Promising Clinical Trial Progress:
The successful interim analysis of the Phase III TIGeR-PaC clinical trial, which aims for a 6-month Overall Survival (OS) benefit, is a significant milestone. The Data Monitoring Committee's recommendation to continue the trial indicates the potential effectiveness of RenovoRx, Inc. (Nasdaq: RNXT)’s TAMP™ platform in treating pancreatic cancer. Industry stakeholders may see value in the company's progress toward meeting primary and secondary endpoints. (29)
7. Visionary Leadership:
CEO Shaun Bagai's commitment to improving cancer care and delivering novel targeted combination therapies is evident in RenovoRx, Inc. (Nasdaq: RNXT)’s mission. His leadership and the company's focus on transformative solutions position RenovoRx as a player with a vision to alter the current paradigm of oncology care. (29)
Source 1: https://www.maximgrp.com/wp-content/uploads/2023/01/Research-Universe_1.13.23.pdf
Source 2: https://www.barchart.com/stocks/quotes/RNXT/price-history/historical
Source 3: https://www.sofi.com/learn/content/understanding-low-float-stocks/
Source 4: https://finviz.com/quote.ashx?t=RNXT&p=d
Source 5: https://www.investopedia.com/terms/n/nanocap.asp
Source 6: https://www.benzinga.com/money/best-nano-cap-stocks
Source 7: https://finance.yahoo.com/news/renovorx-strengthens-intellectual-property-ip-133000702.html
Source 8: https://finance.yahoo.com/news/renovorx-announces-acceptance-four-clinical-133000761.html
Source 9: https://d1io3yog0oux5.cloudfront.net/_d7299d6f72a9b4207e890ff7fb18b17c/renovorx/db/2223/20908/pdf/Non-con+RNXT+IR+Deck_2023-06-22.pdf
Source 10: https://pbs.twimg.com/media/EDrTVVFXYAA5EFj.jpg
Source 11: https://www.forbes.com/advisor/wp-content/uploads/2021/04/nyse.jpg
Source 12: https://www.investopedia.com/terms/p/pricetarget.asp
Source 13: https://www.maximgrp.com/team_members/jason-mccarthy-ph-d/
Source 14: https://www.maximgrp.com/about-us/
Source 15: https://www.linkedin.com/posts/maxim-group_maxim-group-2022-year-end-review-activity-7019388769157967872-lTRd/?originalSubdomain=gr
Source 16: https://schrts.co/zAGgvMtJ
Source 17: https://www.thebalancemoney.com/triangle-chart-patterns-and-day-trading-strategies-4111224
Source 18: https://investmentu.com/low-float-stocks/
Source 19: https://www.raps.org/RAPS/media/news-images/news-images/FDA-Logo.jpg
Source 20: https://renovorx.com/wp-content/uploads/2021/05/square-catheter.jpg
Source 21: https://pancan.org/news/five-year-pancreatic-cancer-survival-rate-increases-to-12/
Source 22: https://www.marketwatch.com/investing/stock/rnxt?mod=search_symbol
Source 23: https://schrts.co/RptJryQN
Source 24: https://www.otcmarkets.com/stock/RNXT/overview (as of 11/14/2023)
Source 25: https://finance.yahoo.com/news/renovorx-initiates-patient-enrollment-university-123000346.html
Source 26: https://renovorx.com/wp-content/uploads/2019/11/NewBeautyImage-1024×576.jpg
Source 27: https://www.investopedia.com/terms/n/nanocap.asp
Source 28: https://www.benzinga.com/money/best-nano-cap-stocks
Source 29: https://finance.yahoo.com/news/renovorx-reports-third-quarter-2023-133000876.html
Source 30: https://www.benzinga.com/quote/RNXT/analyst-ratings
Source 31: https://www.tipranks.com/stocks/rnxt/forecast
Source 32: https://schrts.co/bQGcGGDq
Source 33: https://d1io3yog0oux5.cloudfront.net/_7432738ba51df07b35ca397236ce22b0/renovorx/db/2223/20930/pdf/RNXT+IR+Deck_2023-11-06-2023-2.pdf
Source 34: https://www.verywellhealth.com/stage-4-pancreatic-cancer-5093642
Source 35: https://www.roswellpark.org/sites/default/files/2021-07/adobestock_181431116.jpg
Source 36: https://seekingalpha.com/symbol/RNXT
Legal Disclaimer
This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
COMPENSATION
Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 11/14/2023 and ending on 11/16/2023 to publicly disseminate information about (GEVI:US) via digital communications. We have been paid fifty thousand dollars USD. We own zero shares of (GEVI:US)